Health and Healthcare

Health and Healthcare Articles

Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Intra-Cellular Therapy shares practically doubled on Monday after the firm announced that the FDA has approved Caplyta for the treatment of schizophrenia in adults
NewLink Genetics and Merck shares made handy gains on Friday after it was announced that the FDA has granted approval to Ervebo, the Zaire Ebola virus vaccine V920.
Stealth Bio shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy (PMM). Specifically, the top-line...
This Wedbush analyst sees close to 200% in potential upside in Paratek Pharmaceuticals beyond the massive one-day gain on Thursday.
The U.S. Department of Health and Human Services has awarded Paratek Pharmaceuticals a pact to support development of its treatment for pulmonary anthrax.
When most investors and consumers think of antitrust issues and monopolies, they probably think of big giant multinational companies with billions of dollars in sales and assets and likely even...
Syros Pharma and Global Blood Therapeutics shares were on the move on Wednesday after the companies announced a collaboration to develop and commercialize novel therapies for sickle cell disease and...
Solid Biosciences shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy.
Adamas Pharma shares dropped sharply on Tuesday after the firm reported results from its late-stage multiple sclerosis study.
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval.
Proteostasis shares were absolutely crushed on Tuesday after the firm announced midstage data from its cystic fibrosis study. What comes next?
The influenza season officially runs from October to as late as May each year. Activity peaks around the end of the year and into January, which means that the U.S. is in its peak period. In some...
Prevail Therapeutics shares jumped early on Tuesday after the firm announced that the FDA has granted Orphan Drug designation for its dementia treatment.
Goldman Sachs believes that several health care companies can win, and it has three top picks for 2020 that may seem counterintuitive.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.